Blood plasma pseudouridine in patients with malignant proliferative diseases

• Published in: European journal of clinical chemistry and clinical biochemistry Vol. 31; no. 11; p. 765
• Main Authors: Motyl, T, Traczyk, Z, Cieśluk, S, Daniewska-Michalska, D, Kukulska, W, Kałuzny, Z, Podgurniak, M, Orzechowski, A, Debski, B
• Format: Journal Article
• Language: English
• Published: Germany 01.11.1993
• Subjects: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor - blood; Chromatography, High Pressure Liquid; Creatinine - blood; Female; Humans; Male; Middle Aged; Neoplasms - blood; Neoplasms - physiopathology; Neoplasms - urine; Pseudouridine - blood; Pseudouridine - urine
• ISSN: 0939-4974

The blood plasma concentration of pseudouridine was estimated in 104 healthy adult subjects, and 108 patients suffering from malignant proliferative diseases. The HPLC method for simultaneous determination of pseudouridine and creatinine was applied. The average physiological concentration of pseudouridine in blood plasma was 2.43 +/- 0.97 mumol.l-1 or 29.15 +/- 7.40 mmol.mol-1 creatinine. The physiological urinary excretion of pseudouridine was 14.32 +/- 5.20 mumol.24 h-1.kg-0.75 or 19.60 +/- 5.22 mmol.mol-1 creatinine. Renal clearance of pseudouridine and endogenous creatinine were 4.04 +/- 0.99 and 5.50 +/- 1.46 ml.kg-0.75, respectively. A positive correlation (r = 0.55, P < 0.01) was found between age (in the range 20-92 years) and blood plasma pseudouridine concentration (mumol.l-1). By expressing plasma pseudouridine in relation to plasma creatinine, the apparent influence of non-metabolic factors (age, renal insufficiency, blood dilution) on the plasma pseudouridine concentration were largely excluded. Among haematological proliferative diseases the highest values of plasma pseudouridine concentrations were observed in chronic lymphocytic leukaemia (8.19 mumol.l-1; 54.9 mmol.mol-1 creatinine) and multiple myeloma (7.02 mumol.l-1; 52.5 mmol.mol-1 creatinine). In multiple myeloma, but not in chronic lymphocytic leukaemia, the plasma pseudouridine concentration depended on the clinical stage. A lower, but still significant response in non-Hodgkin's lymphoma was noted (4.03 mumol.l-1; 40.88 mmol.mol-1 creatinine). A significant increase of the plasma pseudouridine concentration was characteristic of adenocarcinomas of the large intestine, and it occurred in the early stages of malignant growth. In patients with lung cancer the plasma pseudouridine concentration was elevated only in advanced cases with metastases.